DOCSLIB.ORG

Clinmass® TDM Kit System Therapeutic Drug Monitoring (TDM) by LC-MS/MS

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Clinmass® TDM Kit System Therapeutic Drug Monitoring (TDM) by LC-MS/MS Novel LC-MS/MS Kit System for Therapeutic Drug Monitoring ClinMass® TDM Kit System Therapeutic Drug Monitoring (TDM) by LC-MS/MS The ClinMass® TDM Kit System is based on a universal TDM Plat- Benefits of the ClinMass® TDM Kit System form (order no. MS9000). It allows to enlarge the spectrum of analytical parameters by simple combination of the ClinMass® • Determination of currently 131 different analytes using TDM Platform with any ClinMass® Add-on Set. Select your ana- - one TDM Platform1 lyte panel by choosing the suitable ClinMass® Add-on Sets! - one analytical column • Simple one-step sample preparation for a quick sample processing 1i.e. identical sample preparation and mobile phases Currently available ClinMass® Add-on Sets 35 Benzodiazepines (BZP) 15 Tricyclic Antidepressants (TCA) 26 Antiepileptic Drugs (AED) 27 Antidepressants (ADP) 28 Neuroleptics (NLP) Additional Add-on Sets in preparation: Antimycotics (AMC), Cytostatics (CYT) www.recipe.de One step sample preparation! Analyte survey of the currently available ClinMass® Add-on Sets Add-on Set for Add-on Set for Add-on Set for Add-on Set for Add-on Set for 35 Benzo- 15 Tricyclic 26 Antiepileptic 27 Anti- 28 Neuroleptics diazepines Antidepressants Drugs depressants Order no. MS9500 Order no. MS9100 Order no. MS9200 Order no. MS9400 Order no. MS9300 Alprazolam* Amitriptyline* Carbamazepine* Atomoxetine* Amisulpride* Alprazolam, α-Hydroxy-* Clomipramine* Carbamazepine, 10-OH- Bupropion* Aripiprazole* Bromazepam Clozapine* Carbamazepine-diol Bupropion, erythro-Dihydro- Aripiprazole, Dehydro-* Bromazepam, 3-Hydroxy- Desipramine* Carbamazepine-epoxide Bupropion, Hydroxy- Chlorpromazine* Chlordiazepoxide* Doxepin* N-Desmethylmethsuximide Bupropion, threo-Dihydro-* Chlorprothixene* Clobazam Imipramine* Ethosuximide* Citalopram* Clozapine* Clonazepam* Maprotiline* Felbamate* Clomethiazole Flupentixol* Clonazepam, 7-Amino-* Norclomipramine* Gabapentine Dosulepin* Fluphenazine* Demoxepam Norclozapine* Lacosamide* Duloxetine* Haloperidol* Diazepam* Nordoxepin* Lamotrigine* Fluoxetine* Levomepromazine* Estazolam* Normaprotiline Levetiracetam* Fluoxetine, Desmethyl-* Melperone* Flunitrazepam* Nortrimipramine Oxcarbazepine* Fluvoxamine* Norclozapine* Flunitrazepam, 7-Amino-* Nortriptyline* PEMA* Mianserine* Norquetiapine Flunitrazepam, Desmethyl- Protriptyline Perampanel Milnacipran* Olanzapine* Flurazepam Trimipramine* Phenobarbital* Mirtazapine* Olanzapine, Desmethyl- Flurazepam, Desalkyl- Phenytoin Mirtazapine, Desmethyl- Paliperidone (9-OH-Risperidone)* Lorazepam* Pregabaline* Moclobemide* Perazine* Lormetazepam Primidone* Opipramol* Pipamperone* Medazepam Retigabine* Paroxetine* Promethazine* Midazolam* Rufinamide Reboxetine* Prothipendyl* Midazolam, α-Hydroxy-* Stiripentol* Ritalinic Acid Quetiapine* Nitrazepam* Sulthiame Sertraline* Risperidone* Nitrazepam, 7-Amino- Tiagabine* Sertraline, Desmethyl-* Sertindole* Norclobazam Topiramate* Tranylcypromine* Sulpiride* Nordiazepam* Valproic Acid* Trazodone Thioridazine* Oxazepam* Zonisamide* Venlafaxine* Ziprasidone* Prazepam* Venlafaxine, O-Desmethyl- Zotepine Temazepam* Zuclopenthixol* Tetrazepam Trazodone Triazolam* Triazolam, α-Hydroxy-* Zaleplon Zolpidem* Zopiclone *Internal standard contains stable isotope-labelled substance One step sample Antiepileptic Drugs (AED) preparation! LC Parameters Binary HPLC pump: Mobile Phase A/B (0.6 ml/min) Injection volume: 1 - 10 µl Injection interval: 4.5 min Column heater: 40 °C Chromatogram ClinCal® Serum Calibrator, Level 2 (order no. MS9213) 8.0 Pregabaline 0.86 Lamotrigine 2.16 7.2 Gabapentin 0.87 10-OH-Carbamazepine 2.29 6.4 Levetiracetam 0.93 Phenobarbital 2.39 5.6 Phenylethylmalonamide N-Desmethylmethsuximide 4.8 (PEMA) 1.17 (NDMS) 2.62 Ethosuximide 1.29 Carbamazepine-Epoxide 2.70 * Reconstitution of IS 4.0 MS Parameters Primidone 1.60 Oxcarbazepine 2.98 with Precipitant P 3.2 Valproic acid 1.68 Topiramate 3.04 2.4 Sultiame 1.70 Carbamazepine 3.36 Ion source: Electrospray Ionisation (ESI) 1.6 Lacosamide 1.80 Phenytoin 3.37 0.8 Zonisamide 1.83 Tiagabine 3.41 0.0 Felbamate 2.03 Retigabine 3.63 MS/MS mode: MRM Carbamazepine-Diol 2.08 Perampanel 3.94 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.4 Rufinamide 2.13 Stiripentol 4.07 Benzodiazepines (BZP) Antidepressants (ADP) LC Parameters LC Parameters Binary HPLC pump: Mobile Phase A/B (0.6 ml/min) Binary HPLC pump: Mobile Phase A/B (0.7 ml/min) Injection volume: 1 - 10 µl Injection volume: 1 - 10 µl Injection interval: 6.8 min Injection interval: 3.5 min Column heater: 40 °C Column heater: 40 °C Chromatogram Chromatogram ClinCal® Serum Calibrator, Level 2 (order no. MS6013) ClinCal® Serum Calibrator, Level 2 (order no. MS9413) 3.8e6 3.4e6 Ritalinic acid 0.76 Opipramol 1.68 Tranylcypromine 0.89 Paroxetine 1.69 3.0e6 O-Desmethylvenlafaxine 0.92 Mirtazapine 1.70 2.6e6 Moclobemide 1.13 Fluvoxamine 1.78 2.2e6 Desmethylmirtazapine 1.15 Trazodone 1.78 Milnacipran 1.15 Duloxetine 1.81 1.8e6 intensity (cps) OH-Bupropion 1.21 Desmethylfluoxetine 1.83 1.4e6 Venlafaxine 1.27 Bupropion 1.88 erythro-Dihydro-Bupropion Dosulepin 1.96 1.0e6 threo-Dihydro-Bupropion 1.28* Fluoxetine 1.96 6.0e5 Clomethiazole 1.33 Norsertraline 2.10 2.0e5 Citalopram 1.55 Sertraline 2.30 0.0 Reboxetine 1.58 Mianserin 2.51 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 2.2 2.4 2.6 Atomoxetine 1.67 Tricyclic Antidepressants (TCA) Neuroleptics (NLP) LC Parameters LC Parameters Binary HPLC pump: Mobile Phase A/B (0.8 ml/min) Binary HPLC pump: Mobile Phase A/B (0.65 ml/min) Injection volume: 1 - 10 µl Injection volume: 1 - 10 µl Injection interval: 3.8 min Injection interval: 5.5 min Column heater: 40 °C Column heater: 40 °C Chromatogram Chromatogram ClinCal® Serum Calibrator, Level 2 (order no. MS9113) ClinCal® Serum Calibrator, Level 2 (order no. MS9313) intensity (cps) intensity (cps) Ordering Information TDM Platform Order No. Description Quantity MS9000 ClinMass® TDM Platform 1 pce. for 400 assays Content (order no. MS9000) MS9005 Autosampler Washing Solution 1000 ml MS9007 Mobile Phase A 2 x MS9007 (2 x 1000 ml) MS9008 Mobile Phase B 1000 ml MS9020 Sample Preparation Vials 4 x MS9020 (4 x 100 pcs.) MS9021 Precipitant P 2 x MS9021 (2 x 25 ml) Start Accessories MS9030 Analytical Column with test chromatogram 1 pce. MS9032 Prefilter 1 pce. Accessories MS9022 Diluting Solution D 50 ml Add-On Sets The ClinMass® Add-on Sets contain all analyte specific com- ponents required: Optimisation Mixes, Internal Standards IS, Serum Calibrator Set, Serum Control Set and User Manual Order No. Description Quantity MS9100 ClinMass® Add-on Set for Tricyclic Antidepressants in Serum / Plasma 1 pce. for 200 assays MS9200 ClinMass® Add-on Set for Antiepileptic Drugs in Serum / Plasma 1 pce. for 200 assays MS9300 ClinMass® Add-on Set for Neuroleptics in Serum / Plasma 1 pce. for 200 assays MS9400 ClinMass® Add-on Set for Antidepressants in Serum / Plasma 1 pce. for 200 assays MS9500 ClinMass® Add-on Set for Benzodiazepines in Serum / Plasma 1 pce for 200 assays The ClinMass® TDM Kit System is additionally available for on-line SPE analysis (ClinMass® “TDM Kit System, on-line”). V1 - 02/2017 RECIPE Chemicals + Instruments GmbH Certified according to Dessauerstraße 3 Phone +49 / 89 / 54 70 81 - 0 EN ISO 9001 80992 Munich/ Germany [email protected] EN ISO 13485 www.recipe.de.
Load more

Recommended publications
  • 2015-02 Toxicology Rapid Testing Panel
    SOUTH CAROLINA LAW ENFORCEMENT DIVISION NIKKI R. HALEY MARK A. KEEL Governor Chief FORENSIC SERVICES LABORATORY CUSTOMER NOTICE 2015-02 REGARDING TOXICOLOGY RAPID TESTING PANEL August 12, 2015 This notice is to inform the Coroners of South Carolina of a new testing panel available through the SLED Toxicology Department. On Monday, August 17th, the Toxicology Department will begin offering both a Rapid Testing Panel in addition to the already available Expanded Testing Panel. This Rapid Testing Panel is to be utilized in cases where the Expanded Testing Panel is not warranted, specifically where a cause of death has already been established. The Rapid Testing Panel will consist of volatiles analysis, to include, ethanol, acetone, isopropanol and methanol, drug screens, and drug confirmation/quantitation of positive screens. The cases assigned to the Rapid Testing Panel will have an expedited turnaround time. Targeted turn around times will be two weeks for negative cases and six weeks or less for positive cases. While every effort will be made to adhere to these time frames, additional time may be required on occasion due to the nature of postmortem samples. Submitters will be notified if there is a problem with a particular sample. Please see attachment regarding specifically which substances are covered by the Rapid Testing Panel and the Expanded Testing Panel. As always, a detailed case history and list of drugs suspected is appreciated. Rapid Panel and Expanded Panel will be choices available in iLAB. Please contact Lt. Dustin Smith (803-896-7385) with additional questions. ALI-359-T An Accredited Law Enforcement Agency P.O.
    [Show full text]
  • Clinical Trial of the Neuroprotectant Clomethiazole in Coronary Artery Bypass Graft Surgery a Randomized Controlled Trial Robert S
    Anesthesiology 2002; 97:585–91 © 2002 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Clinical Trial of the Neuroprotectant Clomethiazole in Coronary Artery Bypass Graft Surgery A Randomized Controlled Trial Robert S. Kong, F.R.C.A.,* John Butterworth, M.D.,† Wynne Aveling, F.R.C.A.,‡ David A. Stump, M.D.,† Michael J. G. Harrison, F.R.C.P.,§ John Hammon, M.D.,ʈ Jan Stygall, M.Sc.,# Kashemi D. Rorie, Ph.D.,** Stanton P. Newman, D.Phil.†† Background: The neuroprotective property of clomethiazole THE efficacy of coronary artery bypass surgery in the has been demonstrated in several animal models of global and relief of angina and in some circumstances in enhancing Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/97/3/585/335909/0000542-200209000-00011.pdf by guest on 29 September 2021 focal brain ischemia. In this study the authors investigated the life expectation is now accepted. It is a tribute to the low effect of clomethiazole on cerebral outcome in patients under- mortality of the procedure that interest is now focused going coronary artery bypass surgery. Methods: Two hundred forty-five patients scheduled for on the neurologic and neuropsychological complica- 1–3 coronary artery bypass surgery were recruited at two centers tions. Adverse neurologic outcomes have been found and prospectively randomized to clomethiazole edisilate to occur in 2–6% of patients and neuropsychological (0.8%), 225 ml (1.8 mg) loading dose followed by a maintenance deficits in 10–30%.4–6 These complications are consid- dose of 100 ml/h (0.8 mg/h) during surgery, or 0.9% NaCl ered to be ischemic in nature, being a consequence of (placebo) in a double-blind trial.
    [Show full text]
  • A Retrospective Comparison of Inappropriate Prescribing Of
    Schjøtt and Aßmus BMC Medical Informatics and Decision Making (2019) 19:102 https://doi.org/10.1186/s12911-019-0821-0 RESEARCHARTICLE Open Access A retrospective comparison of inappropriate prescribing of psychotropics in three Norwegian nursing homes in 2000 and 2016 with prescribing quality indicators Jan Schjøtt1,2* and Jörg Aßmus3 Abstract Background: Inappropriate prescribing of psychotropics is a persistent and prevalent problem in nursing homes. The present study compared inappropriate prescribing of psychotropics in nursing homes 16 years apart with prescribing quality indicators. The purpose was to identify any change in inappropriate prescribing of relevance for medical informatics. Methods: Three Norwegian nursing homes were audited in 2000 and 2016 with regard to prescribing quality. Psychotropics among 386 patients in 2000, and 416 patients in 2016, included combinations of antidepressants, antipsychotics, anxiolytics-hypnotics, and antiepileptics. Prescribing quality indicators included psychotropic polypharmacy (defined as concurrent use of three or more psychotropics) and potential inappropriate psychotropic substances or combinations. Furthermore, potential clinically relevant psychotropic interactions were classified as pharmacodynamic or pharmacokinetic using an interaction database. The first ranked (most important) interaction in each patient was selected with the following importance of categories in the database; recommended action > documentation > severity. Three levels (from low to high) within each category were used for ranking. Results: From 2000 to 2016, psychotropic polypharmacy increased from 6.2 to 29.6%, potential inappropriate psychotropic substances was reduced from 17.9 to 11.3% and potential inappropriate psychotropic combinations increased from 7.8 to 27.9%. Changes in polypharmacy and combinations were predominantly associated with prescribing of anxiolytics-hypnotics.
    [Show full text]
  • Pharmacological Treatments in Insomnia
    Pharmacological treatments in insomnia Sue Wilson Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College, London Drugs used in insomnia Licensed for insomnia •GABA-A positive allosteric modulators •melatonin (modified release) •promethazine •diphenhydramine •doxepin (USA) Unlicensed prescribed frequently •antihistamines (and OTC) •antidepressants Sometimes prescribed drugs for psychosis Some GABA-A positive allosteric modulators Drugs acting at the GABA-A benzodiazepine receptor zopiclone zolpidem zaleplon benzodiazepines eg temazepam, lorazepam (safe in overdose, as long as no other drug involved) Drugs acting at the barbiturate/alcohol receptor chloral hydrate/chloral betaine clomethiazole (dangerous in overdose) GABA calms the brain Gamma aminobutyic acid (GABA) is the main inhibitory transmitter in the mammalian central nervous system. It plays the principal role in reducing neuronal excitability and its receptors are prolific throughout the brain, in cortex, limbic system, thalamus and cerebellum sedative Increase anticonvulsant GABA anxiolytic function ataxia, memory effects Effects of GABA-A positive allosteric modulators •These drugs enhance the effect of GABA, the main inhibitory neurotransmitter in the brain •They all produce sedation, sleep promotion, ataxia, muscle relaxation, effects on memory, anticonvulsant effects •Therefore for insomnia the duration of action of the drug is important – these effects are unwanted during the day Effects of these GABA-ergic drugs on sleep EEG/PSG • Appearance of
    [Show full text]
  • Boendedok 2020 Manual För Intervjuformulären
    BoendeDOK 2020 Manual för intervjuformulären Mikael Dahlberg Mats Anderberg Helen Falck Innehållsförteckning Introduktion ___________________________________________________ 4 BoendeDOK __________________________________________________ 6 Inskrivningsintervju __________________________________________ 6 Avstämningsintervju __________________________________________ 7 Utskrivningsintervju __________________________________________ 7 Frågeområden i BoendeDOK ___________________________________ 7 Hantering och förvaring av DOK-material _________________________ 8 Kontaktpersonens roll _________________________________________ 8 Kodning i BoendeDOK ________________________________________ 9 Tidsintervaller ______________________________________________ 10 Frågor om förändring ________________________________________ 10 Att i efterhand ändra intervjusvar _______________________________ 11 Inför intervjun - Klientens samtycke ____________________________ 11 Under intervjun _____________________________________________ 12 Återkoppling av Inskrivningsintervjun ___________________________ 12 BoendeDOK Inskrivningsformulär ________________________________ 16 Intervjuinformation __________________________________________ 16 A. Administrativa uppgifter ___________________________________ 16 B. Bakgrundsinformation _____________________________________ 17 C. Boende _________________________________________________ 17 D. Relationer _______________________________________________ 20 E. Myndighets- och vårdkontakter ______________________________ 21
    [Show full text]
  • Assessment Report
    12 October 2017 EMA/833636/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report Referral under Article 29(4) of Directive 2001/83/EC Alcover (granules in sachet) and associated names INN: Sodium oxybate Procedure number: EMEA/H/A-29(4)/1451 Note: Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background Information ......................................................................... 3 2. Scientific discussion ................................................................................ 3 2.1. Introduction ...................................................................................................... 3 2.2. Assessment of the issues raised as a potential serious risk to public health............... 4 3. Benefit-risk assessment ........................................................................ 11 3.1. 3.1 Initial benefit-risk balance assessment ......................................................... 11 3.2. 3.2 Re-examination procedure .......................................................................... 13 3.2.1. CHMP discussion on grounds for re-examination .................................................
    [Show full text]
  • Drug-Facilitated Sexual Assault Panel, Blood
    DRUG-FACILITATED SEXUAL ASSAULT PANEL, BLOOD Blood Specimens (Order Code 70500) Alcohols Analgesics, cont. Anticonvulsants, cont. Antihistamines, cont. Ethanol Phenylbutazone Phenytoin Cyclizine Amphetamines Piroxicam Pregabalin Diphenhydramine Amphetamine Salicylic Acid* Primidone Doxylamine BDB Sulindac* Topiramate Fexofenadine Benzphetamine Tapentadol Zonisamide Guaifenesin Ephedrine Tizanidine Antidepressants Hydroxyzine MDA Tolmetin Amitriptyline Loratadine MDMA Tramadol Amoxapine Oxymetazoline* Mescaline* Anesthetics Bupropion Pyrilamine Methcathinone Benzocaine Citalopram Tetrahydrozoline Methamphetamine Bupivacaine Clomipramine Triprolidine Phentermine Etomidate Desipramine Antipsychotics PMA Ketamine Desmethylclomipramine 9-hydroxyrisperidone Phenylpropanolamine Lidocaine Dosulepin Aripiprazole Pseudoephedrine Mepivacaine Doxepin Buspirone Analgesics Methoxetamine Duloxetine Chlorpromazine Acetaminophen Midazolam Fluoxetine Clozapine Baclofen Norketamine Fluvoxamine Fluphenazine Buprenorphine Pramoxine* Imipramine Haloperidol Carisoprodol Procaine 1,3-chlorophenylpiperazine (mCPP) Mesoridazine Cyclobenzaprine Rocuronium Mianserin* Norclozapine Diclofenac Ropivacaine Mirtazapine Olanzapine Etodolac Antibiotics Nefazodone Perphenazine Fenoprofen Azithromycin* Nordoxepin Pimozide Hydroxychloroquine Chloramphenicol* Norfluoxetine Prochlorperazine Ibuprofen Ciprofloxacin* Norsertraline Quetiapine Ketoprofen Clindamycin* Nortriptyline Risperidone Ketorolac Erythromycin* Norvenlafaxine Thioridazine Meclofenamic Acid* Levofloxacin* Paroxetine
    [Show full text]
  • Uniform Classification Guidelines for Foreign Substances and Recommended Penalties Model Rule
    DRUG TESTING STANDARDS AND PRACTICES PROGRAM. Uniform Classification Guidelines for Foreign Substances And Recommended Penalties Model Rule. January, 2018 (V.13.4) Ó ASSOCIATION OF RACING COMMISSIONERS INTERNATIONAL – 2018. Association of Racing Commissioners International 1510 Newtown Pike, Lexington, Kentucky, United States www.arci.com Page 1 of 61 Preamble to the Uniform Classification Guidelines of Foreign Substances The Preamble to the Uniform Classification Guidelines was approved by the RCI Drug Testing and Quality Assurance Program Committee (now the Drug Testing Standards and Practices Program Committee) on August 26, 1991. Minor revisions to the Preamble were made by the Drug Classification subcommittee (now the Veterinary Pharmacologists Subcommittee) on September 3, 1991. "The Uniform Classification Guidelines printed on the following pages are intended to assist stewards, hearing officers and racing commissioners in evaluating the seriousness of alleged violations of medication and prohibited substance rules in racing jurisdictions. Practicing equine veterinarians, state veterinarians, and equine pharmacologists are available and should be consulted to explain the pharmacological effects of the drugs listed in each class prior to any decisions with respect to penalities to be imposed. The ranking of drugs is based on their pharmacology, their ability to influence the outcome of a race, whether or not they have legitimate therapeutic uses in the racing horse, or other evidence that they may be used improperly. These classes of drugs are intended only as guidelines and should be employed only to assist persons adjudicating facts and opinions in understanding the seriousness of the alleged offenses. The facts of each case are always different and there may be mitigating circumstances which should always be considered.
    [Show full text]
  • A Complete Toxicology Screening Procedure for Drugs and Toxic Compounds in Urine and Plasma Using LC-MS/MS
    Application Note: 449 A Complete Toxicology Screening Procedure for Drugs and Toxic Compounds in Urine and Plasma Using LC-MS/MS Marta Kozak, Taha Rezai, Thermo Fisher Scientific, San Jose, CA Introduction Key Words Toxicology laboratories commonly use automated Scan Event 1 Scan Event 7 + Full Scan MS – Full Scan MS • ToxSpec immunoassays, gas chromatography-mass spectrometry Analyzer (GC-MS) and high pressure liquid chromatography-diode array detector (HPLC-DAD) techniques to perform • ToxID Software toxicology screening analyses. None of these techniques • LXQ Linear Ion are able to identify all the drugs and toxic compounds Trap that are potentially present in a sample. Implementation of liquid chromatography-mass spectrometry (LC-MS) for • Clinical toxicology screening provides specific and sensitive Toxicology analysis of drugs and toxic substances. The benefits of the • General LC-MS/MS screening methodology include a simple Unknown sample preparation procedure, ease of adding new Screening compounds to the screening method and fewer limitations based on compound volatility and thermal stability. In Scan Event 2-6 Scan Event 8-9 addition, Thermo Scientific ToxID automated toxicology + MS/MS on parent list – MS/MS on parent list screening software is able to automatically generate both Summary and Long Reports, avoiding the need for Figure 1: MS scan events manual analysis of each sample chromatogram. This application note describes the use of the Thermo Scientific LXQ ion trap mass spectrometer equipped with an ESI source and HPLC for identification of unknown compounds in human urine and human plasma. Step 1: Extract analytes from urine or plasma with SPE procedure Goal To develop a complete LC-MS/MS screening methodology which includes a sample preparation method, LC-MS Step 2: Analyze the samples method, spectra library, and data processing and reporting with LC-MS/MS method software.
    [Show full text]
  • Förordning Om Ändring I Förordningen (1992:1554) Om Kontroll Av Narkotika;
    Príloha 11 k rozhodnutiu švédskych úradov vlády 22. februára 2018 § 79 1. ------IND- 2018 0079 S-- SK- ------ 20180302 --- --- PROJET Zbierka zákonov Švédska SFS Published on issued on 1 March 2018. The government hereby lays down1 that Annex 1 to the Ordinance (1992:1554) on the control of narcotic drugs2 shall read as set out below. This ordinance shall enter into force on 10 April 2018. On behalf of the Government ANNIKA STRANDHÄLL Lars Hedengran (Ministry of Health and Social Affairs) 1 See Directive (EU) 2015/1535 of the European Parliament and of the Council of 9 September 2015 laying down a procedure for the provision of information in the field of technical regulations and of rules on Information Society services. 2 Ordinance reprinted as 1993:784. 1 SFS Annex 13 List of substances to be considered narcotic drugs according to the Narcotic Drugs Punishments Act Stimulants of the central nervous system ethylamphetamine (2-ethylamino-1-phenylpropane) fenethylline [1-phenyl-1-piperidyl-(2)-methyl]acetate 1-phenyl-2-butylamine N-hydroxyamphetamine propylhexedrine 4-methylthioamphetamine (4-MTA) modafinil 4-methoxy-N-methylamphetamine (PMMA, 4-MMA) 2,5-dimethoxy-4-ethylthiophenethylamine (2C-T-2) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) 4-iodo-2,5-dimethoxyphenethylamine (2C-I) 2,4,5-trimethoxyamphetamine (TMA-2) 4-methylmethcathinone (mephedrone) 4-fluoramphetamine 1-(4-methoxyphenyl)-2-(methylamino)propan-1-one (methedrone) 1-(1,3-benzodioxol-5-yl)-2-pyrrolidin-1-yl-pentan-1-one (MDPV) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one
    [Show full text]
  • Tert-Butanol)
    EPA/635/R-13/107 Preliminary Materials www.epa.gov/iris Preliminary Materials for the Integrated Risk Information System (IRIS) Toxicological Review of tert-Butyl Alcohol (tert-Butanol) [CASRN 75-65-0] July 2013 NOTICE This document is comprised of preliminary materials, consisting of a literature search strategy, evidence tables, and exposure-response arrays. This information is distributed solely for the purpose of pre-dissemination review under applicable information quality guidelines. It has not been formally disseminated by EPA. It does not represent and should not be construed to represent any Agency determination or policy. It is being circulated for review of its technical accuracy and science policy implications. National Center for Environmental Assessment Office of Research and Development U.S. Environmental Protection Agency Washington, DC Preliminary Materials for the IRIS Toxicological Review of tert-Butanol DISCLAIMER This document is comprised of preliminary materials for review purposes only. This information is distributed solely for the purpose of pre-dissemination review under applicable information quality guidelines. It has not been formally disseminated by EPA. It does not represent and should not be construed to represent any Agency determination or policy. Mention of trade names or commercial products does not constitute endorsement or recommendation for use. This document is a draft for review purposes only and does not constitute Agency policy. ii DRAFT—DO NOT CITE OR QUOTE Preliminary Materials for the IRIS Toxicological Review of tert-Butanol CONTENTS PREFACE ........................................................................................................................................................ v 1. DRAFT LITERATURE SEARCH STRATEGY .............................................................................................. 1-1 1.1. Literature Search and Screening Strategy for tert-Butanol .......................................................... 1-1 1.2.
    [Show full text]
  • Identification of the Cytochrome P450 Enzymes Involved in the Oxidative
    RSC Advances View Article Online PAPER View Journal | View Issue Identification of the cytochrome P450 enzymes involved in the oxidative metabolism of trantinterol Cite this: RSC Adv.,2018,8, 34764 using ultra high-performance liquid chromatography coupled with tandem mass spectrometry† Kunjie Li, Xingjie Guo, Feng Qin, Zhili Xiong, Longshan Zhao * and Jia Yu * Trantinterol is a novel b2-adrenoceptor agonist used for the treatment of asthma. This study aimed to identify the cytochrome P450 enzymes responsible for the metabolism of trantinterol to form 4-hydroxylamine trantinterol (M1) and tert-butyl hydroxylated trantinterol (M2), which was achieved using the chemical inhibition study, followed by the metabolism study of trantinterol in a panel of recombinant CYPs, as well as the kinetic study with the appropriate cDNA-expressed P450 enzymes. A highly selective and sensitive ultra high-performance Creative Commons Attribution-NonCommercial 3.0 Unported Licence. liquid chromatography tandem mass spectrometry method was developed and validated for the simultaneous determination of M1 and M2. The inhibition study suggested that CYP2C19 and CYP3A4/5 were involved in the formation of M1 and M2, and CYP2D6 only contributed to the formation of M1. Assays with cDNA- expressed CYP enzymes further showed that the relative contributions of P450 isoforms were 2C19 > 3A4 > 2D6 > 2E1 for the formation of M1, and 3A4 > 2C19 > 2D6 for the formation of M2. The enzyme kinetic analysis was then performed in CYP2C19, CYP2D6 and CYP3A4. The kinetic parameters were determined and normalized with respect to the human hepatic microsomal P450 isoform concentrations. All the results Received 23rd July 2018 support the conclusion that CYP3A4 and CYP2C19 are the major enzymes responsible for formation of M1 Accepted 4th October 2018 and M2, while CYP2D6 and CYP2E1 also engaged to a lesser degree.
    [Show full text]